An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial

A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease

Ophthalmology.

Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE

doi: 10.1016/

RECOMMENDED

Dry Eye Disease

Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: Results from two pivotal clinical trials

Ocul Surf.

Sheppard JD, Torkildsen GL, Geffin JA, Dao J, Evans DG, Ousler GW, Wilson J, Baba SN, Senchyna M, Holland EJ

doi: 10.1016/j.jtos.2018.11.009.

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

Eur J Ophthalmol.

Nichols KK, Donnenfeld ED, Karpecki PM, Hovanesian JA, Raychaudhuri A, Shojaei A, Zhang S

doi: 10.1177/1120672118791936.

Dry Eye Disease

Impact of upper blepharoplasty, with or without orbicularis oculi muscle removal, on tear film dynamics and dry eye symptoms: A randomized controlled trial

Acta Ophthalmol

Hollander MHJ, Pott JWR, Delli K, Vissink A, Schepers RH, Jansma J

doi: 10.1111/aos.15036

Dry Eye Disease

The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

J Clin Med

van Setten GB, Baudouin C, Horwath-Winter J, Böhringer D, Stachs O, Toker E, Al-Zaaidi S, Benitez-Del-Castillo JM, Beck R, Al-Sheikh O, Seitz B, Barabino S, Reitsamer HA, Müller-Lierheim WGK

doi: 10.3390/jcm9113536

Dry Eye Disease

Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease

Invest Ophthalmol Vis Sci.

Cohn GS, Corbett D, Tenen A, Coroneo M, McAlister J, Craig JP, Gray T, Kent D, Murray N, Petsoglou C, Baba SN, Holland EJ

doi: 10.1167/iovs.18-23984.

Dry Eye Disease

The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease

Ocul Surf.

Hussain M, Shtein RM, Pistilli M, Maguire MG, Oydanich M, Asbell PA, DREAM Research Group.

doi: 10.1016/j.jtos.2019.08.002.

Dry Eye Disease

Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial

Ophthalmology

Wirta D, Vollmer P, Paauw J, Chiu KH, Henry E, Striffler K, Nau J, ONSET-2 Study Group.

doi: 10.1016/j.ophtha.2021.11.004

Dry Eye Disease

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease

Ophthalmology.

Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD

doi: 10.1016/j.ophtha.

Related content

A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease

Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: Results from two pivotal clinical trials

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

Impact of upper blepharoplasty, with or without orbicularis oculi muscle removal, on tear film dynamics and dry eye symptoms: A randomized controlled trial

The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease

The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease

Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease